Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Controlled, Double-Masked, Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray in Subjects With Neurotrophic Keratopathy (the Olympia Study)

NCT04957758 is registered in ClinicalTrials.gov with Oyster Point Pharma, Inc. as lead sponsor.

NCT NCT04957758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04957758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Controlled, Double-Masked, Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray in Subjects With Neurotrophic Keratopathy (the Olympia Study)
Lead sponsor
Oyster Point Pharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 17, 2021
Completion date
April 28, 2023
Enrollment
113 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

neurotrophic keratopathy